4:36 PM ยท 27 January 2025

Massive sell-off in Allakos shares following disappointing clinical trial results for AK006 ๐Ÿ“‰

Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.

 

Source: xStation

16 July 2026, 6:46 PM

Daily Summary: ๐Ÿ“‰ A Red Day Across Markets. AI Sector Weighs on Wall Street, Precious Metals Under Pressure

16 July 2026, 4:00 PM

Stock of the Week: ASML โ€“ The Machines Driving the Future of Semiconductors

16 July 2026, 3:14 PM

Netflix down 45% from its peak ๐Ÿšฉ What will the streaming giant's earnings reveal?

16 July 2026, 3:00 PM

US Open: Blood on Wall Street as Semiconductor Sector Extends Correction

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits